Vanguard Group Inc Raises Position in Spark Therapeutics Inc (ONCE)

Share on StockTwits

Vanguard Group Inc increased its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 2.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,823,168 shares of the biotechnology company’s stock after purchasing an additional 67,846 shares during the period. Vanguard Group Inc owned 0.07% of Spark Therapeutics worth $154,005,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FMR LLC grew its stake in shares of Spark Therapeutics by 2.6% during the 2nd quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock valued at $458,206,000 after buying an additional 142,428 shares during the period. BlackRock Inc. grew its position in shares of Spark Therapeutics by 5.6% during the 3rd quarter. BlackRock Inc. now owns 3,031,043 shares of the biotechnology company’s stock valued at $165,344,000 after buying an additional 161,811 shares during the last quarter. Vanguard Group Inc. grew its position in Spark Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,823,168 shares of the biotechnology company’s stock worth $154,005,000 after purchasing an additional 67,846 shares during the last quarter. Partner Fund Management L.P. grew its position in Spark Therapeutics by 37.5% in the 2nd quarter. Partner Fund Management L.P. now owns 876,779 shares of the biotechnology company’s stock worth $72,562,000 after purchasing an additional 239,143 shares during the last quarter. Finally, EcoR1 Capital LLC bought a new position in shares of Spark Therapeutics in the third quarter valued at approximately $45,661,000.

Shares of ONCE stock opened at $43.60 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 10.36. The company has a market cap of $1.67 billion, a P/E ratio of -5.71 and a beta of 1.98. Spark Therapeutics Inc has a 52-week low of $34.53 and a 52-week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). The business had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The firm’s quarterly revenue was up 463.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.90) earnings per share. Research analysts expect that Spark Therapeutics Inc will post -1.53 EPS for the current year.

ONCE has been the topic of several research reports. Cantor Fitzgerald set a $103.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, October 1st. Raymond James reissued a “buy” rating on shares of Spark Therapeutics in a report on Friday, September 21st. William Blair restated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, September 21st. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research report on Wednesday, October 10th. Finally, Guggenheim started coverage on shares of Spark Therapeutics in a research note on Tuesday, October 9th. They issued a “buy” rating and a $70.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $65.20.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://weekherald.com/2019/01/11/vanguard-group-inc-raises-position-in-spark-therapeutics-inc-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply